Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Malignant Lymphoma

Free Subscription 09.02.2026 1 Am J Hematol 1 Biochem Biophys Res Commun 1 Blood 2 BMC Cancer 1 Br J Dermatol 5 Eur J Haematol 1 J Natl Cancer Inst 2 Leuk Lymphoma 3 Leukemia

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. ESCRIBANO-SERRAT S, Beyar-Katz O, Shouval R, Dahi PB, et al
   CD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
   Am J Hematol. 2026 Jan 30. doi: 10.1002/ajh.70218.
   PubMed        
   
   

   
   Biochem Biophys Res Commun

2. INOUE Y, Shimura Y, Niiyama-Uchibori Y, Chinen S, et al
   Multistep molecular trajectory of monocytic myeloid-derived suppressor cell induction by diffuse large B-cell lymphoma cells.
   Biochem Biophys Res Commun. 2026;804:153287.
   PubMed         Abstract available
   
   

   
   Blood

3. 
   Liu X, Zhang Q, Guo H, Pan Q, Zhou K. Bendamustine, gemcitabine, and vinorelbine (BeGEV) regimen followed by ASCT induces durable remissions in PD-(L)1 inhibitor-resistant refractory/relapsed classical Hodgkin lymphoma: a single-center, long-term stud
   Blood. 2026;147:703.
   PubMed        
   
   

   
   BMC Cancer

4. FUJITA K, Kajiya K, Lee S, Morishita T, et al
   Real-world outcome and dose intensity of Pola-R-CHP versus R-CHOP/R-THP-COP in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective cohort study.
   BMC Cancer. 2026 Feb 5. doi: 10.1186/s12885-026-15584.
   PubMed        
   
   
5. ZHAO J, Lian J, Wen X, Ma L, et al
   Prognostic factors and nomogram development for adult diffuse large B-cell lymphoma: a single-center retrospective cohort study.
   BMC Cancer. 2026 Feb 3. doi: 10.1186/s12885-026-15642.
   PubMed        
   
   

   
   Br J Dermatol

6. GAN X, Wu Y, Sun X, Zhao A, et al
   Chimeric antigen receptor T-cell therapy for relapsed/refractory primary cutaneous B-lymphoblastic lymphoma with rapid and durable systemic regression.
   Br J Dermatol. 2025 Dec 2:ljaf484. doi: 10.1093.
   PubMed        
   
   

   
   Eur J Haematol

7. DUMINUCO A, Del Fabro V, Santuccio G, Chiarenza A, et al
   Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life Study.
   Eur J Haematol. 2026;116:235-244.
   PubMed         Abstract available
   
   
8. RAJABIAN N, Axler O, Wisten E, Porwit A, et al
   Restricted Expression of the Constant Region 1 of T-Cell Receptor beta by Flow Cytometry Facilitates Detection of T-Cell Neoplasms With High Specificity but Moderate Predictive Value.
   Eur J Haematol. 2026;116:245-255.
   PubMed         Abstract available
   
   
9. JELICIC J, Juul-Jensen K, Bukumiric Z, Rask Kragh Jorgensen R, et al
   Validation of US Consensus Eligibility Criteria for Front-Line DLBCL Trials.
   Eur J Haematol. 2026;116:290-301.
   PubMed         Abstract available
   
   
10. SKAFI M, Caserta S, Vigna E, Bruzzese A, et al
    Frontline Therapy in Diffuse Large B-Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions.
    Eur J Haematol. 2026 Feb 3. doi: 10.1111/ejh.70129.
    PubMed         Abstract available
    
    
11. THIEBLEMONT C, Colrat F, Sellami R, Sivignon M, et al
    Cost-Effectiveness Analysis of Second-Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B-Cell Lymphoma.
    Eur J Haematol. 2026 Feb 6. doi: 10.1111/ejh.70131.
    PubMed         Abstract available
    
    

    
    J Natl Cancer Inst

12. DAKHALLAH N, Steglich J, Gowdy C, Milgrom SA, et al
    Imaging pitfalls in pediatric, adolescent, and young adult hodgkin lymphoma: a SEARCH for CAYAHL initiative to bridge multidisciplinary patient care.
    J Natl Cancer Inst. 2026 Jan 30:djag016. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

13. GUPTA Y, Hurst E, Publicover A, Jardine L, et al
    Glofitamab as a salvage therapy postallogenic hematopoietic stem cell transplant in relapsed-refractory Burkitt lymphoma.
    Leuk Lymphoma. 2026 Feb 5:1-3. doi: 10.1080/10428194.2026.2624667.
    PubMed        
    
    
14. YOSHIDA K, Mushino T, Tanaka K, Kosako H, et al
    Distribution of CD30-positive tumor cell proportions in adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2026 Feb 3:1-5. doi: 10.1080/10428194.2026.2622526.
    PubMed        
    
    

    
    Leukemia

15. YANG ZZ, Kim HJ, Tang X, Novak JP, et al
    Malignant B cells expressing SIRPalpha are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma.
    Leukemia. 2026 Feb 4. doi: 10.1038/s41375-026-02872.
    PubMed        
    
    
16. NIKKARINEN A, Almlof J, Osterroos A, Ladenvall C, et al
    Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma.
    Leukemia. 2026 Feb 4. doi: 10.1038/s41375-026-02861.
    PubMed        
    
    
17. STEIN CM, Hablesreiter R, Christen F, Lowe P, et al
    Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation.
    Leukemia. 2026;40:314-324.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum